WHO implementation tool for monitoring the toxicity of new antiretroviral and antiviral medicines in HIV and viral hepatitis programmes; 2018 (Sólo en inglés)

Overview

In the current context of treatment being rapidly scaled up, prolonged exposure to ARV drugs and transition to new antiretroviral (ARV) drugs, ARV toxicity clearly needs to be monitored to better understand the risks of ARV drugs under the conditions of actual use.

This implementation tool describes the recommended approaches for routine monitoring of toxicity integrated with the national monitoring and evaluation system and targeted approaches to monitoring toxicity to enable enhanced monitoring and reporting of treatment-limiting toxicity to support country implementation and generation of local data.

In addition to recognizing the linkages, coinfected populations and commonalities across TB, hepatitis B and C and with the aim of encouraging integration, this tool also highlights the recommended toxicity monitoring approaches and existing tools across these disease areas.